Related Experiment Videos
WR-2721 reduces bone loss after hindlimb tenotomy in rats
J L Shaker1, M D Fallon, S Goldfarb
1Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104.
Summary
WR-2721, a cysteamine analog, was tested for its effects on disuse osteoporosis in rats. This compound significantly reduced bone loss and osteoclast activity, suggesting a therapeutic potential for osteoporosis.
Area of Science:
- Pharmacology
- Orthopedics
- Bone Biology
Background:
- WR-2721 is a thiophosphate analog of cysteamine.
- Previous research indicates WR-2721 may induce hypocalcemia through effects on parathyroid hormone secretion, bone resorption, and calcium reabsorption.
Purpose of the Study:
- To investigate the efficacy of WR-2721 in mitigating bone loss in a rat model of disuse osteoporosis.
- To determine if WR-2721 influences osteoclast activity in this model.
Main Methods:
- Disuse osteoporosis was induced in rats via unilateral knee tenotomy.
- Animals were treated daily with WR-2721 (240 mg/kg).
- Bone loss was assessed by measuring femoral weight, and osteoclast numbers were quantified in tibial bone.
Main Results:
- Tenotomy led to significant increases in osteoclast numbers and reductions in femoral weight.
- WR-2721 treatment prevented 26% of femoral dry weight loss and 29% of ashed weight loss after 14 days.
- WR-2721 significantly reduced osteoclast counts in tenotomized tibias at both 3 and 14 days post-procedure.
Conclusions:
- WR-2721 demonstrates a protective effect against bone loss in a rat model of disuse osteoporosis.
- The data suggest that WR-2721's bone-sparing effect is mediated, at least in part, by the inhibition of osteoclastic bone resorption.